GRI Bio presents preclinical data from pipeline of NKT Cell Modulators

GRI Bio announced Vipin Kumar Chaturvedi, PhD, Chief Scientific Officer of GRI Bio presented encouraging preclinical data from the Company’s preclinical studies of type 2 NKT activating molecules, GRI-0803 and GRI-0124 at the 14th International Congress on Autoimmunity held May 17-20, 2024 in Ljubljana, Slovenia. Key Highlights Observed from GRI Preclinical Studies: Data demonstrate iNKT cells accumulate in SLE patients and in NZBWF1 mice, have an activated phenotype and their hyporesponsiveness to in vitro stimulation suggests chronic activation; Type 2 NKT cells accumulate in NZBWF1 kidney, and remain responsive to in vitro restimulation; Type 2 NKT cell activation in NZBWF1 mice inhibits iNKT cell activity; Once-weekly GRI-0124: Inhibited pro-inflammatory cytokines and signaling pathways in NZBWF1 mice; Decreased pDC accumulation and MHC class II expression; Inhibited CD4+, CD8+ T cells, and B cells; Reduced renal cellular infiltration and fibrosis; Inhibited proteinuria, anti-dsDNA Ig, and improved overall survival and proteinuria-free survival; GRI-0803 has demonstrated: Chemistry backbone based on type 2 GRI-0124; less than400g/mol; Favorable solubility profile; Excellent bioavailability; PK profile supporting q.d. administration orally; No CV toxicology issues observed, no genotox and no activation or inhibition within CYP450 pathway; No toxicology concerns to date